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Objective: Maternal lifestyle during pregnancy has an effect of gestational development and neonatal
outcome. Overweight gravidas and gravidas with excessive weight gain have an increased risk of
gestational complications and neonatal metabolic disorder. The underlying mechanisms are still under
discussion, but the hormonally active fat mass and its biomarkers, adipocytokines, may play a key role by
potentially having a direct impact on the metabolic homeostasis of the system in concert with other
biomarkers like hepatokines and myokines. Up to now little is known in terms of lifestyle habits and their
effect on this complex model on maternal and fetal outcome. Therefore, we aim to investigate the in-
ﬂuence of maternal lifestyle clusters during pregnancy on the maternal and fetal biomarkers of com-
partments, speciﬁcally those implying maternal fat and muscle mass, maternal liver and the placenta and
who are associated with maternal body composition and birth weight.
Methods: In this exploratory pilot study at least 100 singleton pregnancies and their newborns will be
included. The women will undergo assessments of anthropometric measurements, venous blood sam-
ples will be drawn and physical activity and nutritional status will be collected through questionnaires.
Newborns will undergo assessments of anthropometric measurements, umbilical cord samples will be
drawn and birth outcomes will be evaluated. We will measure adipokines, myokines and hepatokines
and relate them to maternal lifestyle clusters and fetal outcome.
Conclusion: Our study will be the ﬁrst to examine the relationship between maternal body composition,
birth weight and potential biomarkers based on an innovative compartment model.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Incidences of overweight and metabolic syndrome in children
increase worldwide, thereby increasing the risk for developing
chronic diseases in later life. This is negatively inﬂuenced by pre-
maturity, fetopathia diabetic, maternal obesity and gestational
diabetes (GDM) [1]. Maternal obesity is an important factor of
excessive birth weight and increasing risk for later obesity and
metabolic disorder [2]. The additional cause next to genetic pre-
disposition is assumed to be perinatal programming. This process
describes the reaction of the developing embryonic organs, such asibert), C.Graf@dshs-koeln.de
Inc. This is an open access article uthe hypothalamus, to the intrauterine environment inﬂuenced by
the mother. One of the inﬂuences that is prominently known to
affect the embryonic organs is the mother’s nutrition. The perinatal
programming may have lifelong consequences to metabolism as a
result from faulty materno-placental nutrient supply [3]. Therefore,
children’s longeterm reaction to carbohydrates and amino acids
are programmed during sensitive fetal phases by the maternal
“offer” [4]. Our compartment model describes the individual
metabolically active organs and their known endocrinological
functions. The effect of those organ systems upon each other and
onto themother’s entiremetabolism and that impact on the fetus is
the basis of our examinations. Particular endocrinological factors
such as insulin and leptin, but also other biomarkers such as adi-
ponectin, resistin and TNF-alpha (TNF-a) play a key role in the
development of GDM [5,6]. Examples show that these cytokines
originate from different compartments like maternal liver, muscle,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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responding with each other and more or less with the fetus (Fig. 1).
Of the biomarkers to be researched, the following is known about
their function and mechanisms of action: Leptin is secreted in ad-
ipose tissue with serum levels proportional to the adipose mass. It
has been demonstrated that obese subjects have higher levels than
subjects with healthy body weight [11e13]. Another operant
regulator of glucose homeostasis is resistin from adipose tissue,
muscle cells, endothelial cells, placental villi and throphoblasts
[11,14,15]. Some studies found a positive correlation between
resistin levels and body fat mass, others do not conﬁrm this link
[14]. Serum levels ﬁrst increase during the third trimester and then
at term. The effect of the maternal metabolism is an increase in
insulin resistance. Higher umbilical resistin levels at term increase
neonatal hepatic glucose production and may protect neonatal
hypoglycemia [15]. Adiponectin is expressed contrary to leptin, in
that it enhances insulin sensitivity by increasing insulin activity and
reducing glucose production. In obese mothers adiponectin levels
are reduced. Presumably adiponectin is produced in the human
placenta [16,17]. The present adipokines may affect pregnancy
outcome and fetal growth. Leptin and resistin levels in GDM are
controversial, while data relating to adiponectin levels show a
decrease in GDM.
The increase of fat mass in pregnancy is associated with an
exacerbated inﬂammatory state. Higher circulation concentrations
of inﬂammatory cytokines like C-reactive protein (CRP),
Interleukin-6 (IL-6) and TNF-a are detected [18e20]. Also identiﬁed
are myokines, a subspecies of cytokines which have a role in ex-
ercise associated metabolic adaption [21]. Myokines probably have
a beneﬁcial effect regarding chronic disease. Little is known about
their impact during pregnancy. Brain-derived neurotrophic factor
(BDNF) is identiﬁed as a regulator of controlling body fat mass and
energy balance [21,22]. Low serum levels are associated with
obesity and diabetes mellitus type 2 [23]. In contrast, physical ac-
tivity may increase serum levels [22,24]. Irisin levels are inversely
correlated with obesity, diabetes mellitus and GDM. Irisin pre-
cursors are expressed by the placenta. Mothers with GDM have
signiﬁcantly lower irisin levels than those without GDM [25].
FetuinA is a hepatokine associated with insulin resistance during
pregnancy and is detected as an acute phase protein [26].
As shown in Table 1, the relevance of individual biomarkers has
been established. However, the intricate interactions amongst and
between biomarkers and compartments remain largely unknown.
This pilot study intends to detect these interactions between the
different lifestyle factors (nutrition and physical exercise) and
relevant biomarkers. In order to do so, blood from the mother andTable 1
Selected cytokines during pregnancy (modiﬁed to D'Ippolito et al., 2012 [28]).
Cytokines Leptin Adiponectin Resistin
Maternal
Circulating
levels
↑ ↓ ↑
( 3.Trim)
Metaboliceffects growth of adipose
tissue
increases insulin
activity and sensitivity;
reduces glucose production
increases
insulin resista
Fetal
Umbilical level
at term
↑ ↑ ↑
Function increases: throphoblast-
proliferation; IL-
expression; VEGF-
secretion; placental
lipolysis (?)
decreases of transplacental
insulin-mediated
amino acid transport;
enhancement fetal
insulin sensitivity
increases hepa
glucose produ
protect of neo
hypoglycemia
[ ¼ upregulation, Y ¼ downregulation, [/Y ¼ upregulation as wall as downregulation pthe baby at the time of birth will be sampled from a vein and the
umbilical cord respectively. Also, both their anthropometric data
will be registered as well as the mother’s lifestyle factors deter-
mined by means of retrospective questionnaire. The aim of the
study is to examine the inﬂuence of maternal lifestyle clusters on
maternal weight gain, birth weight and the underlying biomarkers.
2. Material and methods
2.1. Ethical consideration
Wewill conduct a pilot study in a cross-sectional cohort over a 5
month period at the German Sport University Cologne and the
University Bonn Medical School, Germany. The protocol was sub-
mitted to the University Bonn Medical School Ethics Committee
and approved under the number 269/13. Also, the following pro-
cedures will be followed: Participation in the study will only occur
after reading the consent form and giving written consent. All
women will be guaranteed the right to not participate in the study.
The study will be carried out in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki). We will
ensure conﬁdentially of the collected data and document numbers
(identiﬁcations).
2.2. Subjects and sample size
This study will include women who are admitted for delivery at
the labor ward, Department of Obstetrics and Gynecology, Uni-
versity Bonn, with a singleton pregnancy and gestational age be-
tween 36 and 42 weeks who have given written consent. Women
with multiple pregnancy, gestational age <36 weeks, the inability
to speak German, mental illness and a high-risk pregnancy will be
excluded from the study. The target sample size is 100 mothers and
their newborns. Nearly all quantitative studies can be subjected to a
sample size calculation. However, they may be of little value in
early exploratory studies where scarce data are available on which
to base the calculations (though this may be addressed by per-
forming a pilot study ﬁrst and using the data from that) [27].
2.3. Anthropometric and clinical data
Clinical data such as height or pregnancy related diseases are
retrieved from the patients' antenatal and inpatient ﬁles. We will
also consider aspects during pregnancy and relating to birth which
may be important variables including: maternal age, parity,
ethnicity, level of education, smoking and GDM during pregnancy,IL-6 TNF-a Irisin BDNF FetuinA
↑ ↑
(3.Trim)
↑/↓ ↑/↓ ↑
(2.Trim)
nce
? reduces
insulin sensitivity
negatively
correlated
with GDM
positively
correlated
with
exercises
increases
insulin resistance;
acute phase protein;
fat accumulation
in liver
? ? ? ? ?
tic
ction;
natal
Regulates
hepatic
immune
response
increases placenta
inﬂammation
? ? negative regulation
of neonatal bone
development (?)
ossible, ? ¼ currently no data available.
Fig. 1. Adipokine-myokine-hepatokine compartment model.
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during childbirth. Furthermore, maternal body weight before de-
livery will be measured by the gynecologist at the preceding
appointment and will be retrieved from the antenatal chart.
Women’s Body Mass Index (BMI ¼ kg/m2) will be calculated by
body weight in relation to body size. To estimate maternal weight
gainwewill use the self-reported pre-pregnancy weight. To classify
women’s weight gain during pregnancy we will use the Institute of
Medicine (IOM) guidelines based on BMI (Table 2).
Anthropometric measurements will be performed during
admission for delivery. Maternal mid-arm circumferences will be
measured on the right side to the nearest 0.1 cm with a non-
extensible, ﬂexible tape. Skinfold thickness will be measured using
a Harpenden skinfold caliper (John Bull British Indicators Ltd.,
Harpenden UK) with a constant pressure of 10 g/mm2. The proce-
dure will be carefully standardized and the measurement will be
made in triplicate; the results will be averaged. Three points are
measured to the nearest 0.2 mm: triceps, thigh, and suprailiac [29].
In addition, we will estimate neonatal Ponderal Index
(PI ¼ 100x(kg/m3)). The birth weight will be measured using an
electronic scale to the nearest 1 g and height will be measured from
crown-heel in the recumbent position to the nearest 1 mm by
midwives within 2 h after delivery.
We will examine the following neonatal outcomes: birth
weight, length, head circumference, and Apgar score; additionally,
the pH in the umbilical cord artery will be analyzed within 10 min
after delivery. Gestational age at birth will be calculated from the
last menstrual period and veriﬁed by ﬁrst-trimester ultrasound
measurements.Table 2
Weight gain recommendations during pregnancy according to the Institute of
Medicine [36] 2009; kg ¼ kilogram; lbs ¼ pounds.
Pre-pregnancy BMI Total weight gain
Range in kg Range in lbs
Underweight (BMI < 18.5 kg/m2) 12.5e18 28e40
normal-weight (BMI 18.5e24.9 kg/m2) 11.5e16 25e35
Overweight (BMI 25.0e29.9 kg/m2) 7e11.5 15e25
Obese (BMI > 30 kg/m2) 5e9 11e202.4. Laboratory value generate from maternal venous blood and
umbilical cord
Venous blood samples will be collected into 7.5 mL serum tube
(S-Monovette; Sarstedt/Germany). The maternal blood sample will
be collected on admission to the labor ward; the umbilical cord
sample will be collected from the placental part of the umbilical
cord immediately after clamping. The samples will be stored at þ4Celsius for a maximum of 48 h. The samples will be centrifuged
(4000 rpm for 10 min at 4 C), and serum will be pipetted into al-
iquots and stored at 20 Celsius until assaying. Samples will be
thawed only once and all reagents will be run in duplicate. Adi-
ponectin and leptin will be measured in a TECAN reader (Nano
Quant inﬁnite M200 Pro, Switzerland) by a direct sandwich ELISA
kit from MERCK/Millipore, Germany, according to the manufac-
turer’s instructions. A seven point standard curve will be generated
and samples will be interrogated with a lower level of detection of
1.28 ng/ml and 0.78 ng/ml for adiponectin and leptin, respectively.
Serum concentrations of TNF-a, IL-6, resistin and BDNF will be
investigated by a multiplex immunoassay from eBioscience con-
ducted according to the manufacturer's instructions. This sandwich
ELISA-like bead-based suspension array allows measurement of
multiple analytes in one well. Measurement of serum duplicates
will be conducted in a Luminex 200 reader (Luminex, Austin, TX,
USA). A seven point standard curve was generated on each plate for
each analyte and samples will be interrogated with a lower level of
detection of 9.1 pg/ml, 9.1 pg/ml, 6.01 pg/ml and 1.88 pg/ml for
TNF-a, IL-6, resistin and BDNF, respectively (calculated with Bio-
Plex Manager 6.1, Bio-Rad, Hercules, CA, USA). In addition, CRP,
Irisin and Fetuin-Awill be measured by a single ELISA kit, according
to manufacturer’s instructions. Insulin will be measured by radio-
immunoassay (RIA Kit; Roche Diagnostics Germany).
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Several questionnaires will be used to measure physical activity,
nutrition and socio-demographic factors. At the beginning, de-
mographics and other covariates such as pre-pregnancy weight,
socioeconomic status, level of education, ethnicity or smoking
habits will be asked by closed questions. To measure physical ac-
tivity before and during pregnancy, we will use the Pregnancy
Physical Activity Questionnaire (PPAQ) as described by Chasan-
Taber et al. [30]. It is a reliable, validated instrument and a
reasonably accurate measure of a broad range of physical activity
during pregnancy.Women are asked to select the category that best
approximates the amount of time spent in 32 activities including
household/caregiving, occupational, sports/exercise, and inactivity
during the current trimester. Womenwill be classiﬁed according to
self-reported physical activity. Time spent in each activity will be
multiplied by its intensity to calculate the average “daily total en-
ergy expenditure inMetabolic Equivalent of Task (MET)e hours per
day. In addition, activity will be classiﬁed in the following intensity
groups: sedentary (<1.5 METs), light (1.5  3.0 METs), moderate
(3.0e6.0 METs) or vigorous (>6.0 METs) [30]. To assess nutrition
during pregnancy, we will use a semi-quantitative food frequency
questionnaire with pregnancy-speciﬁc adaptations as described
elsewhere. The nutritional part of the questionnaire records the
dieting behavior of the women and collects data about the
consumed amounts of the separate food groups: grains, meat, ﬁsh,
dairy, fruit and vegetables. Additional categories are beverages and
supplements. The questionnaire supplies data about general di-
etary decisions and behavior and their changes since the beginning
of the pregnancy [31].
2.6. Data analysis
Nutrient calculations will be performed using Prodi ® 6.2 Soft-
ware (Science publishing society Stuttgart 2013, Germany).
We will use linear regression analyses to explore the bivariate
and multivariate effects of physical activity and nutrition (lifestyle
clusters) on maternal weight gain and birth weight. The afore-
mentioned are analyzed in relation to the different biomarkers of
the four compartments (fat mass, muscle mass, liver, placenta) with
regard to the covariates like parity, ethnicity, smoking and GDM.
We will divide physical activity levels during pregnancy into
quartiles and compare the birth weights among the four groups
using analysis of variance. Descriptive comparisons will be calcu-
lated by the standard procedures such as t-test, Analysis of
Covariance (ANCOVA) and chi-square test. All statistical analyses
will be performed using the SPSS statistical package (IBM SPSS
Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.).
3. Discussion
Maternal health and physical activity are important for a healthy
infant outcome [32e35]. Several studies support these ﬁndings, but
little is known about the underlying biological mechanisms
[3,6,15]. Leslie Myatt describes a cascade of fetal programming
beginning at the placenta. Dysfunctions in the placenta effect
changes in trophoblasts and the vascular system of the placenta,
leading to hypoxic conditions that ultimately impair the growth of
the fetus. This oxidative stress may cause retardation in fetal
growth or pregnancy complications such as preeclampsia. It is
being speculated that aberrant hormones are leading to this
development. However, the causes have not been able to be spec-
iﬁed further to date [3]. The study at hand aims to analyze those
correlations and potential key factors in the context of adipokines.
Boa et al. examined 2015 adipokine levels in gravidas with andwithout GDM. They were able to verify that adipokines play a key
role in the development of GDM [6]. Cortelazzi et al. conducted
similar research with resistin and adiponectin. The inﬂuence of the
mother’s energy balance onto the fetal growth has been veriﬁed in
a similar fashion [15]. Still the underlying mechanism has not been
established yet nor the inﬂuence of the maternal lifestyle or body
composition. The goal of this study is, therefore, to examine the
correlation between maternal and infantile biomarkers taking into
consideration the individual lifestyle during pregnancy and the
body composition. Details about the complex interactions between
cytokine pathways and changes in terms of different body
composition and maternal lifestyle may thus be detected. Equally,
more knowledge may be gained about the interaction between
adipokines, myokines and hepatokines, the effect of maternal ex-
ercise and nutrition and how this relates to the fetal programming
and outcome.
To our knowledge, this is the ﬁrst study examining the rela-
tionship between maternal body composition, birth weight and
potential biomarkers based on this compartment model. Therefore,
we developed this pilot study project with the intention to incor-
porate a statewide study in numerous centers.
Results of the presented study might offer the relationship be-
tween weight gain in pregnancy, maternal lifestyle (physical ac-
tivity and nutrition) with maternal and fetal biomarkers and
potential birth complications. The authors envision that attained
knowledge will serve as a guide to optimal gestational advice and
for improving maternal and fetal health.
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